Net loss widened to $85.1 million compared to $66.9 million in the prior year period.
Gross margin improved to 64.7% from 63.1% year-over-year.
Completed acquisition of Foresight Diagnostics to expand MRD detection capabilities.
High stock-based compensation expense of $95.1 million in a single quarter.
The Q1 2026 filing presents a classic high-growth biotech trade-off: accelerating commercial momentum versus persistent operational losses. Natera has successfully proven that its technology can scale, with over 1 million tests processed in the quarter and a diversifying revenue stream. The ability to grow revenue by nearly 39% while expanding gross margins suggests a viable path toward profitability if the company can eventually contain its aggressive spending on R&D and stock-based compensation. However, the investment thesis remains contingent on Natera's ability to navigate a minefield of legal and regulatory challenges. While the cash position provides a significant buffer, the reliance on equity-based compensation and the looming contingent payments for the Foresight acquisition introduce long-term dilution risks. Investors must weigh the undeniable strength of the product demand and market penetration against the reality of a business that is still burning cash at a significant rate to maintain its growth trajectory.